Not Signed In -
Vaccine Safety Research |
|
|
Clinical Trial: A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chicken Pox)
This study is not yet open for patient recruitment.
Verified by Merck August 2005
|
Purpose
The purpose of this study is to determine whether the refrigerator-stable formulation of an investigational vaccine has a comparable immune response (the body''''s ability to protect against disease) and safety profile to that of the freezer-stable formulation of the vaccine.
| Condition | Intervention | Phase |
|---|---|---|
| Herpes Zoster | Vaccine: An Investigational Vaccine | Phase II Phase III |
MedlinePlus related topics: Shingles
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Bio-equivalence Study
Eligibility
Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Individuals who are at least 50 years of age or older with a history of varicella (chicken pox)
Exclusion Criteria:
- Prior history of herpes zoster (shingles), prior receipt of varicella or zoster vaccine, immunosuppressed.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00130793
Toll Free Number 1-888-577-8839
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_035
Last Updated: August 15, 2005
Record first received: August 11, 2005
ClinicalTrials.gov Identifier: NCT00130793
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
Last Updated: August 15, 2005
Record first received: August 11, 2005
ClinicalTrials.gov Identifier: NCT00130793
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-23
email this page
print this page
bookmark this page
feedback on this page
